替罗非班治疗急性穿支动脉型脑梗死患者的效果  

Effects of Tirofiban in treatment of patients with acute perforating artery cerebral infarction

作　　者：李小刚 LI Xiaogang(Department of Neurology of Dengta Hospital,Anyang 455000 Henan,China)

机构地区：[1]安阳市灯塔医院神经内科,河南安阳455000

出　　处：《中国民康医学》2025年第8期20-22,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:观察替罗非班治疗急性穿支动脉型脑梗死患者的效果。方法:回顾性分析2022年9月至2023年9月该院收治的68例急性穿支动脉型脑梗死患者的临床资料,依据治疗方式不同将其分为对照组与研究组各34例。对照组采用双抗血小板治疗,研究组在对照组基础上联合替罗非班治疗。比较两组治疗前后神经功能缺损程度[美国国立卫生研究院卒中量表(NIHSS)]评分、炎性因子[C反应蛋白(CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)]水平、日常生活能力[改良Rankin量表(mRS)]评分和不良反应发生率。结果:治疗7、14 d后,两组NIHSS评分均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);治疗后,两组CRP、IL-6、TNF-α水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);治疗7、14 d后,两组mRS评分均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:在双抗血小板治疗基础上采用替罗非班治疗急性穿支动脉型脑梗死患者可降低神经功能缺损程度评分、炎性因子水平,以及改善日常生活能力,效果优于单纯双抗血小板治疗。Objective:To observe effects of Tirofiban in treatment of patients with acute perforating artery cerebral infarction.Methods:The clinical data of 68 patients with acute perforating artery cerebral infarction admitted to the hospital from September 2022 to September 2023 were retrospectively analyzed.According to different treatment methods,they were divided into control group and study group,34 cases in each group.The control group was treated with dual antiplatelet therapy,while the study group was treated with Tirofiban on the basis of that of the control group.The neurological deficit degree[National Institutes of Health stroke scale(NIHSS)]scores,the inflammatory factors[C-reactive protein(CRP),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)]levels,the activities of daily living[modified Rankin scale(mRS)]score before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:After 7 and 14 days of treatment,the NIHSS scores of the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CRP,IL-6 and TNF-αin the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After 7 and 14 days of treatment,the mRS scores of the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:On the basis of the dual antiplatelet therapy,Tirofiban in the treatment of the patients with acute perforating artery cerebral infarction can reduce the neurological deficit scores and the inflammatory factor levels,and improve the activities of daily living.M

关 键 词：急性穿支动脉型脑梗死 替罗非班 神经功能缺损程度 日常生活能力 炎性因子 不良反应 

分 类 号：R743.3[医药卫生—神经病学与精神病学]